EPS for Arbutus Biopharma Corp (ABUS) Expected At $-0.38

October 7, 2017 - By Ellis Scott

 EPS for Arbutus Biopharma Corp (ABUS) Expected At $ 0.38

Investors wait Arbutus Biopharma Corp (NASDAQ:ABUS) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.38 earnings per share, down $0.07 or 22.58 % from last year’s $-0.31 same quarter earnings. Arbutus Biopharma Corp’s Wall Street analysts see 35.71 % negative EPS growth, taking into account the $-0.28 EPS reproted in the previous quarter, The stock decreased 4.67% or $0.35 on October 6, reaching $7.15. About 319,263 shares traded. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 2.31% since October 8, 2016 and is downtrending. It has underperformed by 19.01% the S&P500.

Arbutus Biopharma Corp (NASDAQ:ABUS) Ratings Coverage

Among 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Arbutus Biopharma had 15 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Chardan Capital Markets with “Buy” on Friday, August 4. The firm earned “Neutral” rating on Friday, October 14 by Chardan Capital Markets. The rating was downgraded by Leerink Swann to “Market Perform” on Friday, August 5. Chardan Capital Markets initiated Arbutus Biopharma Corp (NASDAQ:ABUS) on Monday, May 16 with “Sell” rating. The firm has “Sell” rating given on Friday, July 8 by Chardan Capital Markets. The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) earned “Neutral” rating by Chardan Capital Markets on Tuesday, December 13. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, November 6 report. As per Thursday, June 16, the company rating was upgraded by Chardan Capital Markets. The company was upgraded on Wednesday, November 30 by Chardan Capital Markets. The rating was initiated by Wedbush on Friday, August 7 with “Outperform”.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The company has market cap of $375.08 million. The Firm is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection , a disease of the liver caused by the hepatitis B virus (HBV). It currently has negative earnings. It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology.

More notable recent Arbutus Biopharma Corp (NASDAQ:ABUS) news were published by: Streetinsider.com which released: “Form 8-K Arbutus Biopharma Corp For: Sep 20” on September 20, 2017, also Globenewswire.com with their article: “Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference” published on September 25, 2017, Fool.com published: “Here’s Why Arbutus Biopharma Corp. Stock Soared Today” on September 20, 2017. More interesting news about Arbutus Biopharma Corp (NASDAQ:ABUS) were released by: Seekingalpha.com and their article: “Trading Arbutus After Phase 2 Data: Part 2” published on September 26, 2017 as well as Seekingalpha.com‘s news article titled: “Arbutus Biopharma: Updates To Thesis” with publication date: September 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com